Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900891627> ?p ?o ?g. }
- W2900891627 abstract "Patients in refractory status epilepticus (RSE) may require treatment with continuous intravenous anesthetic drugs (cIVADs) for seizure control. The use of cIVADs, however, was recently associated with poor outcome in status epilepticus (SE), raising the question of whether cIVAD therapy should be delayed for attempts to halt seizures with repeated non-anesthetic antiepileptic drugs. In this study, we aimed to determine the impact of differences in therapeutic approaches on RSE outcome using timing of cIVAD therapy as a surrogate for treatment aggressiveness. This was a retrospective cohort study over 14 years (n = 77) comparing patients with RSE treated with cIVADs within and after 48 h after RSE onset, and functional status at last follow-up was the primary outcome (good = return to premorbid baseline or modified Rankin Scale score of less than 3). Secondary outcomes included discharge functional status, in-hospital mortality, RSE termination, induction of burst suppression, use of thiopental, duration of RSE after initiation of cIVADs, duration of mechanical ventilation, and occurrence of super-refractory SE. Analysis was performed on the total cohort and on subgroups defined by RSE severity according to the Status Epilepticus Severity Score (STESS) and by the variables contained therein. Fifty-three (68.8%) patients received cIVADs within the first 48 h. Early cIVAD treatment was independently associated with good outcome (adjusted risk ratio [aRR] 3.175, 95% confidence interval [CI] 1.273–7.918; P = 0.013) as well as lower chance of both induction of burst suppression (aRR 0.661, 95% CI 0.507–0.861; P = 0.002) and use of thiopental (aRR 0.446, 95% CI 0.205–0.874; P = 0.043). RSE duration after cIVAD initiation was shorter in the early cIVAD cohort (hazard ratio 1.796, 95% CI 1.047–3.081; P = 0.033). Timing of cIVAD use did not impact the remaining secondary outcomes. Subgroup analysis revealed early cIVAD impact on the primary outcome to be driven by patients with STESS of less than 3. Patients with RSE treated with cIVADs may benefit from early initiation of such therapy." @default.
- W2900891627 created "2018-11-29" @default.
- W2900891627 creator A5001380387 @default.
- W2900891627 creator A5010036539 @default.
- W2900891627 creator A5014149325 @default.
- W2900891627 creator A5020498296 @default.
- W2900891627 creator A5026609497 @default.
- W2900891627 creator A5048772912 @default.
- W2900891627 creator A5066685170 @default.
- W2900891627 creator A5070831820 @default.
- W2900891627 date "2018-11-21" @default.
- W2900891627 modified "2023-10-17" @default.
- W2900891627 title "Impact of timing of continuous intravenous anesthetic drug treatment on outcome in refractory status epilepticus" @default.
- W2900891627 cites W1492512073 @default.
- W2900891627 cites W1511457711 @default.
- W2900891627 cites W1976802305 @default.
- W2900891627 cites W1988774842 @default.
- W2900891627 cites W1988978487 @default.
- W2900891627 cites W1994421931 @default.
- W2900891627 cites W2010365207 @default.
- W2900891627 cites W2029569324 @default.
- W2900891627 cites W2030080816 @default.
- W2900891627 cites W2036467957 @default.
- W2900891627 cites W2045765644 @default.
- W2900891627 cites W2056821940 @default.
- W2900891627 cites W2057444523 @default.
- W2900891627 cites W2067395123 @default.
- W2900891627 cites W2070330802 @default.
- W2900891627 cites W2073069032 @default.
- W2900891627 cites W2104047366 @default.
- W2900891627 cites W2131983839 @default.
- W2900891627 cites W2156826201 @default.
- W2900891627 cites W2160022655 @default.
- W2900891627 cites W2165926195 @default.
- W2900891627 cites W2189726121 @default.
- W2900891627 cites W2241479029 @default.
- W2900891627 cites W2273596806 @default.
- W2900891627 cites W2558627353 @default.
- W2900891627 cites W2560157144 @default.
- W2900891627 cites W4248646554 @default.
- W2900891627 doi "https://doi.org/10.1186/s13054-018-2235-2" @default.
- W2900891627 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6249897" @default.
- W2900891627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30463604" @default.
- W2900891627 hasPublicationYear "2018" @default.
- W2900891627 type Work @default.
- W2900891627 sameAs 2900891627 @default.
- W2900891627 citedByCount "9" @default.
- W2900891627 countsByYear W29008916272019 @default.
- W2900891627 countsByYear W29008916272021 @default.
- W2900891627 countsByYear W29008916272022 @default.
- W2900891627 crossrefType "journal-article" @default.
- W2900891627 hasAuthorship W2900891627A5001380387 @default.
- W2900891627 hasAuthorship W2900891627A5010036539 @default.
- W2900891627 hasAuthorship W2900891627A5014149325 @default.
- W2900891627 hasAuthorship W2900891627A5020498296 @default.
- W2900891627 hasAuthorship W2900891627A5026609497 @default.
- W2900891627 hasAuthorship W2900891627A5048772912 @default.
- W2900891627 hasAuthorship W2900891627A5066685170 @default.
- W2900891627 hasAuthorship W2900891627A5070831820 @default.
- W2900891627 hasBestOaLocation W29008916271 @default.
- W2900891627 hasConcept C118552586 @default.
- W2900891627 hasConcept C121332964 @default.
- W2900891627 hasConcept C126322002 @default.
- W2900891627 hasConcept C142424586 @default.
- W2900891627 hasConcept C167135981 @default.
- W2900891627 hasConcept C201903717 @default.
- W2900891627 hasConcept C2777080012 @default.
- W2900891627 hasConcept C2777341932 @default.
- W2900891627 hasConcept C2778162923 @default.
- W2900891627 hasConcept C2778186239 @default.
- W2900891627 hasConcept C42219234 @default.
- W2900891627 hasConcept C44249647 @default.
- W2900891627 hasConcept C71924100 @default.
- W2900891627 hasConcept C72563966 @default.
- W2900891627 hasConcept C87355193 @default.
- W2900891627 hasConceptScore W2900891627C118552586 @default.
- W2900891627 hasConceptScore W2900891627C121332964 @default.
- W2900891627 hasConceptScore W2900891627C126322002 @default.
- W2900891627 hasConceptScore W2900891627C142424586 @default.
- W2900891627 hasConceptScore W2900891627C167135981 @default.
- W2900891627 hasConceptScore W2900891627C201903717 @default.
- W2900891627 hasConceptScore W2900891627C2777080012 @default.
- W2900891627 hasConceptScore W2900891627C2777341932 @default.
- W2900891627 hasConceptScore W2900891627C2778162923 @default.
- W2900891627 hasConceptScore W2900891627C2778186239 @default.
- W2900891627 hasConceptScore W2900891627C42219234 @default.
- W2900891627 hasConceptScore W2900891627C44249647 @default.
- W2900891627 hasConceptScore W2900891627C71924100 @default.
- W2900891627 hasConceptScore W2900891627C72563966 @default.
- W2900891627 hasConceptScore W2900891627C87355193 @default.
- W2900891627 hasIssue "1" @default.
- W2900891627 hasLocation W29008916271 @default.
- W2900891627 hasLocation W29008916272 @default.
- W2900891627 hasLocation W29008916273 @default.
- W2900891627 hasLocation W29008916274 @default.
- W2900891627 hasLocation W29008916275 @default.
- W2900891627 hasLocation W29008916276 @default.
- W2900891627 hasOpenAccess W2900891627 @default.
- W2900891627 hasPrimaryLocation W29008916271 @default.
- W2900891627 hasRelatedWork W1983060009 @default.